- Email: [email protected]
NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis
Biochemical and Biophysical Research Communications xxx (xxxx) xxx
Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc
NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis Zixuan Yang 1, Caiquan Liang 1, Tianyu Wang 1, Qingyun Zou 1, Mengxia Zhou, Yin Cheng, Hu Peng, Zhenhua Ji, Yue Deng, Jianchun Liao**, Huanhai Liu* Department of Otolaryngology-Head and Neck Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China
a r t i c l e i n f o
a b s t r a c t
Article history: Received 17 October 2019 Accepted 5 November 2019 Available online xxx
Allergic rhinitis (AR) is a worldwide highly prevalent nasal inflammatory disease with elusive mechanisms about the regulation of innate immune response. The roles and mechanisms of NLRP3, a typical inflammasome, in AR development remain unclear. Here we investigate the roles of NLRP3 inflammasome activation in the development and progression of AR and try to uncover its potential mechanisms underlying. Wildtype and NLRP3 knockout mice were applied to construct the ovalbumin (OVA)-induced AR model. Caspase-1 specific inhibitor Belnacasan and inflammasome activator ATP were used for adjuvant stimulation of AR-model mice respectively. We found that the production of IL-1b and the activation of inflammasome were increased in both patients and mice with AR. NLRP3 deficiency markedly suppressed AR progression with reduced inflammatory response and epithelium pyroptosis in mice with AR. Furthermore, Caspase-1 inhibitor treatment in vivo ameliorated the development and progression of AR with favorable outcomes. Mechanistically, inflammation augments and nasal mucosa injury during AR were partially due to ASC-specks accumulation and subsequent cell pyroptosis. Our study reveals the previously unknown roles of NLRP3 inflammasome in promoting the development and progression of AR via enhancing inflammatory response and epithelium pyroptosis and thus provides a potential clue for allergic disease interventions. © 2019 Elsevier Inc. All rights reserved.
Keywords: NLRP3 Inflammasome IL-1b Allergic rhinitis Pyroptosis
1. Introduction With astonishing increasing new cases every year, allergic rhinitis (AR) has been recognized as one of the major chronic inflammatory upper airway diseases around the world, affecting approximately 20%e30% of the population [1]. Although AR is not fatal and frequently ignored, the effective treatments to cure AR is still unknown. AR patients suffer plenty of both physical discomfort and psychological stress with poor life quality [2]. Currently, several mechanisms underlying the development and regulation of AR have been proposed, with an intense concentration on Th2 immune response and eosinophils infiltration, which shares high similarities with allergic asthma [3,4]. Subsequently, inflammatory microenvironment results in the injury and impaired regeneration of nasal
* Corresponding author. ** Corresponding author. E-mail addresses: [email protected] (J. Liao), [email protected] (H. Liu). 1 These authors contribute equally to this work.
epithelium, which further interrupts the function of olfactory region [5]. Except for eosinophils, innate immune response has been reported to play an important role on the survival and regeneration of olfactory neuroepithelium [6]. However, the molecular mechanism of innate immune molecules in the development and progression of AR has not been thoroughly studied. Recently, inflammasomes activation after infection or stressstimulation has attracted much attention, which was studied most prominently in macrophages and dendritic cells [7]. Nod-like receptors (NLRs) are first discovered sensor proteins to form inflammasome complex, which associate with apoptosisassociated speck-like protein containing a CARD (ASC) through an amino-terminal pyrin domain [8]. Pro-caspase-1 are recruited to the inflammasome and cleaved into active caspase-1 [8]. Active caspase-1 containing cysteine-dependent protease activity, could cleave pro-IL-1b and pro-IL-18 into active IL-1b and IL-18, and then simultaneously induces an inflammatory form of cell death called pyroptosis [9]. Inflammasome activation has been demonstrated to be involved in diverse infectious and nonmicrobial diseases, including pathogenic infections of intestine and lung, gout,
https://doi.org/10.1016/j.bbrc.2019.11.031 0006-291X/© 2019 Elsevier Inc. All rights reserved.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
2
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
autoimmune diseases, Alzheimer’s disease, Type 2 diabetes and so on [10]. As to the allergic response, several studies have shown that certain allergens can trigger inflammasome activation, like house dust mite (HDT) and honey bee venom, which activates inflammasome in keratinocytes and macrophages [11,12]. However, the roles and mechanisms of the inflammasome activation in AR development remain unclear. To figure out the potential correlation between inflammasomes and AR, we detected the production of IL-1b and IL-18 in nasal lavage fluid (NLF) and found it was increased in AR patients compared with that in controls, indicating that activation of inflammasome might play important roles in the development of AR. Moreover, NLR family pyrin domain containing 3 (NLRP3) is the first and most thoroughly studied NLR, which could be induced by Toll-like receptor agonists and TNF-a in macrophages. Thus, we brought in Nlrp3 knockout (Nlrp3/) mice and inflammasome inhibitors for further investigation of the roles of inflammasome activation in nasal epithelium, aiming to discovering new target for AR treatment. 2. Materials and methods 2.1. Clinical specimens 40 AR patients (22 male and 18 female patients; age range, 17e67 years) and 14 healthy subjects (7 male and 7 female subjects; age range, 23e68 years) involved in this study are from Changzheng Hospital (Shanghai, China), who underwent nasal irrigation. Inferior turbinate mucosal samples were collected during septoplasty from the AR patient (female; age, 36 years; with AR and nasal septal deviation) and control (female; age, 26 years; with nasal septal deviation alone). This study was approved by the Ethics Committee of Second Military Medical University (Shanghai, China). All subjects gave written informed consent in accordance with the Declaration of Helsinki. All patients with AR had typical symptoms of perennial nasal allergy and the dust mite skin spot tests were positive. In this study, subjects were excluded if they had received any oral steroid within 3 months before the surgery. Topical steroids and antihistamines were withheld for a minimum of 1 month before the study. None had received antileukotrienes or immunotherapy. 2.2. Animals Six-week-old male C57BL/6 mice were from Shanghai SuperB&K laboratory animal Corp.Ltd. Nlrp3/ mice on a C57BL/6 background with 7bp deficiency at the promoter region of Nlrp3 were donated by Prof. Du Bing from East China Normal University. Mice were maintained under specific-pathogen-free animal laboratory with standard temperature and light controlled animal facility. All animal experiments were undertaken in accordance to the Institutional Animal Care and Use Committee (IACUC) guidelines of Second Military Medical University (Shanghai, China). 2.3. Reagents Antibodies specific to ASC, IL-1b, b-actin, cleaved Gasdermin D and horseradish peroxidase-coupled secondary antibodies were from Cell Signaling Technology. Antibody specific to ASC was from Santa Cruz. Antibodies specific to Caspase-1 and NLRP3 were from Abcam. Imject™ Alum Adjuvant was from ThermoFisher Scientific. Belnacasan (VX-765) was from Selleck. OVA (O-1000-100) was from Biosearch Technologies. DMSO, Lipopolysaccharides from Escherichia coli O111:B4, ATP, Cytotoxicity Detection kit and PEG300 were from Sigma-Aldrich. RPMI-1640 Medium and Fetal Bovine Serum
(FBS) was from Gibco™. 2.4. OVA-induced AR mice model Two stages were included in constructing OVA-induced AR mice model [13,14]. Mice were intraperitoneal injected with 25 mg OVA with 50 ml Imject®Alum as adjuvant once a week for 3 weeks, and controls received the same dosage of saline. One week after the last sensitization, mice were intranasal challenged with 20 ml OVA (50 mg/ml in saline, OVA group) or saline only (saline group) once a day for 7 consecutive days. Belnacasan was dissolved in control (ddH2O with 2% DMSO and 30% PEG 300) at the concentration of 5 mg/mL. Mice were intraperitoneal challenged with control or 5 mg/kg Belnacasan solution each once a day for 7 consecutive days, 10 min before or after OVA challenging. Mice were intraperitoneal challenged with saline (20 mL) or ATP (5 mM in saline) before OVA challenging. In Fig. 3E, mice were intraperitoneal challenged with control or 5 mg/kg Belnacasan each once a day for a week after 7-day-OVA intranasal administration. 15 min after intranasal challenge, frequencies of sneeze and scratch were measured within 15 min, and the data were shown by the average number per minute. The sinonasal cavity structure was processed for histologic analysis, and sinonasal mucosal tissues were harvested for qRT-PCR and Western blot assay. Blood samples were collected from the sinus retro-orbital rout under general anesthesia. 2.5. Cell lines and cultivation Human cell line THP-1 and human nasal epithelial cell line RPMI2650 were purchased from Cell Bank of the Shanghai Academy of life sciences and cultured in the RPMI-1640 medium with 10% FBS at 37 C in a 5% CO2 incubator. 2.6. RNA isolation and qRT-PCR analysis Total RNA was extracted from mice nasal mucosa tissues using TRIzol reagent (Invitrogen) following the manufacturer’s instructions. Real-Time PCR (qRT-PCR) analysis was performed using LightCycler (Roche) and SYBR RT-PCR kit (Takara) as previous introduction [15]. The relative expression level of the individual genes was normalized to that of internal control b-actin by using 2DDCt cycle threshold method. 2.7. Tissue immunohistochemistry (IHC) Nasal mucosa tissues were fixed in 4% PFA and then embedded with paraffin. Dewaxed 3-mm thick sections were treated with 3% H2O2 and then blocked with 3% BSA. Primary antibody were incubated at 4 C overnight. The next day, sections were incubated with secondary antibody for 1 h and then immunostaining was performed using Peroxidase/Diaminobenzidine (DAB) Substrate Kit (Dako) following the standard protocol as we described previously [13]. Photos were taken with Olympus BX53 microscope. 2.8. Immunofluorescence (IF) analysis THP-1 cells slides were labeled with rabbit ASC specific antibody overnight, then labeled with Alexa Fluor 488 mouse anti-rabbit IgG for 1 h, finally coated with fluoroshield mounting medium containing DAPI (ab104139) following the standard protocol as we described previously [13]. Labeled cells slides were viewed with a Zeiss LSM 510 confocal laser microscope.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
3
3. Results
IL-1b and IL-18 in the NLF of AR patients and controls, which showed higher of AR patients than that of controls (Fig. 1A). And patients with mild persistent AR showed lower production of IL-1b than that in patients with moderate to severe persistent AR (Fig. 1A). Furthermore, the production of IL-1b and level of caspase1 were both increased in the inferior turbinate mucosal tissues of AR patients, which were determined by IHC analysis, indicating the crucial roles of inflammasome activation in AR development (Fig. 1B). Simultaneously, we constructed OVA-induced AR mice model, and the behavioral measures of AR indicated that this model had successfully mimicked AR development (Fig. 1C). Whereafter, the production of IL-1b in NLF of mice were detected by ELISA, which also determined increased production of IL-1b during AR development (Fig. 1D). Moreover, IHC analysis showed that AR mice exhibited advanced injury of nasal epithelium tissues, and enhanced expression of ASC, caspase-1 and IL-1b than those of controls (Fig. 1E and F). These data suggest that inflammasome activation might play important roles in the development of AR.
3.1. The production of IL-1b and the activation of inflammasome are increased in both patients and mice with AR
3.2. NLRP3 deficiency inhibits AR progression through alleviating inflammation response in vivo
In order to demonstrate the roles of the inflammasome involving in AR development, we first compared the production of
Currently, the potential function of inflammasome in the AR development is still unconcerned especially lacking in vivo
2.9. ASC-speck isolation and purification ASC-specks were purified from LPS-primed cells activated with ATP, and then passed through a “cushion” of 50% Percoll in CHAPS buffer (20 mM HEPES-KOH, pH 7.5, 5 mM MgCl2, 0.5 mM EGTA, 0.1 mM PMSF and 0.1% CHAPS) for purification. After that, ASCspecks had been washed with 0.5 ml CHAPS buffer and dissolved in PBS. The method of purification is verified as previously described [16,17]. 2.10. Statistics Data are presented as mean ± SD. Statistical comparisons between experimental groups were analyzed by unpaired Student’s ttest in SPSS 17.0 (Chicago, IL), and a two-tailed p < 0.05 was taken to indicate statistical significance. The p values and hazard ratios were shown as indicated. (*, p < 0.05, **, p < 0.01, ***, p < 0.001).
Fig. 1. The production of IL-1b and the activation of inflammasome are increased in both patients and mice with AR. (A) The production of IL-1b and IL-18 in the NLF of AR patients (n ¼ 40) and healthy controls (n ¼ 14) were examined by ELISA analysis. Data are shown as mean ± SD. (B) Representative IHC images show the production of IL-1b and Caspase-1 in the inferior turbinate mucosal tissues. (C) Frequency of scratching and sneezing were examined Caspase in the OVA-induced AR model and control mice. (D) The production of IL-1b in the NLF of mice was examined by ELISA analysis. (E) Representative IHC images show the expression of ASC, IL-1b, and Caspase-1 in the nasal mucosa tissues of mice. (F) Levels of ASC, IL-1b, cleaved Caspase-1 and GSDMD-N was measured by Western blot. The two blots are from two representative of the five mice per group. For CeF, data are shown as mean ± SD (n ¼ 5) or photographs from one representative experiment of three independent experiments. **, p < 0.01, ***p < 0.001.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
4
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
evidence. To further explore this issue, we brought in NLRP3 deficient mice (Nlrp3/), the most studied inflammasome, which showed no abnormality in nasal symptoms of sneezing and scratch (Fig. 2A). Applied with OVA-induced AR model, Nlrp3/ mice exhibited decreased AR symptoms of sneezing and scratch than those of wild-type (WT) mice (Fig. 2A). IHC and Western blot analysis of nasal mucosa confirmed that NLRP3 deficiency effectively inhibited the inflammasome activation in AR mice (Fig. 2B and C). Moreover, the production of IL-1b in NLF of Nlrp3/ mice increased than that of controls (Fig. 2D). Since AR is a typical IgEmediated type I allergic reaction, we compared the content of IgE in the serum between Nlrp3/ and WT mice and found no significant differences (Fig. 2E). Next, we examined the production of
some proinflammatory cytokine and chemokine, and found the production of IL-6, CXCL9 and CXCL10 was decreased in the nasal mucosa tissues of Nlrp3/ mice (Fig. 2F). Furthermore, eosinophils have been considered to play important roles in AR development, thus we detected the cytokines and protein associated with eosinophils activation. And the results showed that NLRP3 deficiency markedly inhibited the production of IL-4, IL-5, IL-13 and the expression of EAR1 in the OVA-induced AR model (Fig. 2F and G). Gasdermin D-N terminal (GSDMD-N), the marker of cell pyroptosis, was reduced in the nasal mucosa tissues of Nlrp3/ mice (Fig. 2H). These data further demonstrate that NLRP3 inflammasome activation contributes to the AR development independent on IgE production.
Fig. 2. NLRP3 deficiency alleviates the AR symptom of mice. Nlrp3/ and WT mice (n ¼ 5) were applied with OVA-induced AR model and nasal mucosa tissues were extracted for examination. (A) Frequency of scratching and sneezing of mice were measured. (B) Representative IHC images show the expression of NLRP3, IL-1b, and Caspase-1 in the nasal mucosa tissues of mice. (C) Levels of NLRP3, IL-1b, and cleaved Caspase-1 were measured by Western blot. (D) The production of IL-1b in the NLF of mice was examined by ELISA analysis. (E) The concentration of IgE in serum of mice was measured by ELISA analysis. (F) Productions of Il-6, Cxcl9, Cxcl10, Il-4, Il-5, and Il-13 were measure by qRT-PCR analysis. (G) The expression of Ear1 was measure by qRT-PCR analysis. (H) Levels of GSDMD-N were measured by Western blot. Data are shown as mean ± SD (n ¼ 5) or photographs from one representative experiment of three independent experiments. *, p < 0.05, **, p < 0.01, ***, p < 0.001.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
5
Fig. 3. Caspase-1 inhibitor ameliorates the AR development. Mice after sensitization were adjuvant challenged with saline or Belnacasan once a day 10 min before OVA challenging (Belnacasan before OVA group) or 10 min after OVA challenging (Belnacasan after OVA group). Mice after sensitization were adjuvant challenged with saline or ATP before OVA challenging (ATP þ OVA group). Mice after 7-day-OVA intranasal administration were challenged with saline or Belnacasan once a day (Belnacasan group). Nasal mucosa tissues were extracted for examination. (n ¼ 5) (A) Representative IHC images show the expression Caspase-1 and IL-1b in the nasal mucosa tissues from OVA-induced AR mice with or without Caspase-1 inhibitor treatment. (B) Levels of IL-1b, and cleaved Caspase-1 were measured by Western blot. (CeE) Frequency of scratching and sneezing of mice were measured in OVA-induced AR mice with Caspase-1 inhibitor or inflammasome activator treatment. (F) The concentration of IgE in serum of mice was measured by ELISA analysis. (G) Productions of Il-6, Cxcl9, Il-4, and expression of Ear1 were measure by qRT-PCR analysis. Data are shown as mean ± SD or photographs from one representative experiment of three independent experiments. *, p < 0.05, **, p < 0.01.
3.3. Caspase-1 inhibitor effectively ameliorates the development of AR As inflammasome activation promotes the development of AR, we consider its possibility to be a potential treatment target with further investigation. Therefore, we applied caspase-1 specific inhibitor (Belnacasan) and inflammasome activator (ATP) adjuvant with OVA through intranasal administration to induce AR respectively. IHC and Western blot analysis of nasal mucosa tissues verified the efficiency of Belnacasan and ATP in inflammasome activation (Fig. 3A and B). The results of AR behavioral symptoms indicated that the inflammasome inhibition dramatically alleviated the development of AR, and conversely inflammasome overactivation aggravated AR development (Fig. 3C and D). We further wondered the function of this inhibitor treatment in the later phase of AR. After OVA intranasal administration for 7 days to successfully establish AR model, mice were treated with Belnacasan for another week. To be excited, we found that the mice exhibited improved AR symptoms (Fig. 3E). Likewise the phenomenon in Nlrp3/ mice, the content of IgE in the serum had no significant change after Belnacasan administration (Fig. 3F). Next, we investigated the production of
proinflammatory cytokines, chemokines, and eosinophilassociated proteins in the nasal mucosa during AR development. The results showed that the production of IL-6, CXCL9, IL-4 and the expression of EAR1 decreased after Belnacasan treatment at mRNA levels (Fig. 3G). Taken together, these proofs further demonstrate that inflammasome inhibition could relieve AR symptoms by inhibiting the inflammatory responses. 3.4. Nasal mucosa injury during AR results from ASC-specks accumulation and subsequent cell pyroptosis Inflammasome activation triggers a form of cell death, called pyroptosis, to protect against infectious agents and cause tissue injury [10], and ASC-specks could be released into extracellular space and uptake by vicinal cells, which retain their ability to mature IL-1b and facilitate cell pyroptosis [16,17]. Since we observed damaged epithelium region with high-expressed IL-1b and Caspase-1 in AR nasal mucosa tissues (Fig. 1B and E), we wondered if ASC-speck accumulation and associated nasal epithelium pyroptosis contributed to the inflammation augments during AR development. To validate this assumption, we applied LPS and ATP stimulus on THP-1 cells respectively, isolated ASC-specks, and
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
6
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
Fig. 4. ASC-specks accumulation and subsequent cell pyroptosis result in epithelial injury. (A) IF staining of ASC was shown of LPS-primed THP-1 cells which then activated with ATP. (BeF) RPMI2650 cells were primed with LPS (1ug/ml) for 6 h and then stimulated with ASC-speck (100ug/ml) for 1 h. IF staining of ASC was shown (B). Production of IL-1b was measured in supernatants by ELISA analysis (C). Levels of IL-1b and cleaved Caspase-1 were detected by Western blot (D). Levels of GSDMD-N were detected by Western blot (E). Quantification of LDH was measured in supernatants (F). Data are shown as mean ± SD (n ¼ 3) or photographs from one experiment of three independent experiments. *, p < 0.05, **, p < 0.01.
stimulated RPMI2650 epithelial cells by LPS and ASC-specks in turn. IF staining showed that ASC-specks formed around the cell membrane in THP-1 cells after inflammasome activation (Fig. 4A), and epithelium could uptake ASC-specks from the supernatant (Fig. 4B). Moreover, the production of IL-1b, cleavage of caspase-1 and GSDMD-N, and the release of LDH were all increased, which indicated that ASC-specks accumulation promoted the nasal epithelium pyroptosis and amplified inflammation (Fig. 4CeF). These results demonstrate that nasal epithelium pyroptosis could be induced by ASC-specks accumulation and augmented inflammation. 4. Discussion The roles of NLRP3 inflammasome and caspase-1 activation in the allergic diseases have attracted much attention recent years, which remains controversial with different allergens like OVA or HDT [18e20]. In our experiments, NLRP3 deficiency alleviates AR progression in the OVA-induced AR mice. Currently, there’s no agreement with a universal mechanism for the NLRP3 inflammasome activation, which occupies multiple effects on cell physiology through IL-1b and IL-18 signaling pathway. It is reported that Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma owing to the function of IL-18 in Treg differentiation [21]. These converse effects of NLRP3 inflammasome in allergic diseases might due to different allergens, tissue microenvironments and downstream activation signaling of NLRP3 inflammasome. Thus, the roles of NLRP3 inflammasome in other allergens-induced allergic airway diseases need to be further studied. In this research, we demonstrated that NLRP3 deficiency or caspase-1 inhibition could relieve AR progression, refrain inflammation response and protect nasal mucosa in vivo. However, caspase-1 and IL-1b cleavage could be activated by multiple inflammasome members, for instance other NLRs and absent in
melanoma 2 (AIM2)-like family members [22]. Thus, we couldn’t rule out the roles of other inflammasomes in the development of AR currently. Moreover, it is reported that AIM2 inflammasome could promote Th2 allergic responses through IL-1b and IL-18 production [12] and intracellular DNA is a classical activator of AIM2 inflammasome [22]. Hence, we couldn’t exclude the possibility that AIM2 inflammasome might be activated by intracellular DNA released during nasal mucosa injury to facilitate AR progression. Thus, whether NLRP3 inflammasome activation promotes AR progression alone or cooperates with other inflammasome members is a critical problem and warrants further investigation. Previous report demonstrated that in the airway epithelial cells, as important immune responders, mitochondrial ROS modulated the allergic airway inflammation through the regulation of NLRP3 inflammasome activation [23]. Here, we confirmed that pyroptosis of epithelium induced by NLRP3 inflammasome activation in nasal mucosa partially contributed to the AR development in vivo and in vitro. However, except for olfactory mucosa epithelium, whether there exists pyroptosis of olfactory neuron or other cells in the nasal microenvironment need to be further figured out more precisely using NLRP3 conditional knockout mice. At present, pharmacotherapies for AR are the mainly treatments to target specific symptoms [24,25], however the current AR treatments cannot achieve the purpose of radical cure. Nowadays, immune modulator therapies provide new approaches for AR treatment and acquire some achievements while still exist some problems [26,27]. For instance, a new TLR8 agonist provides nearterm symptom relief for AR treatment with unclear immunologic mechanisms and uncertain long-term immunomodulatory benefits [28]. Besides, anti-IgE antibodies also exhibit efficacy in AR clinical trials with some limitations of high costs and intravenous therapy [29]. Thus developing more effective treatment schedules of AR is urgently needed, our findings demonstrated that caspase-1 inhibition could effectively relieve symptom of mice both during and after OVA induction, providing a new option for allergy subjects
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
with rapid onset of symptom control and longer-term immunomodulation. Here, we demonstrated NLRP3 deficiency or caspase-1 inhibition suppressed AR progression without serum IgE alteration. Although allergen-mediated cross-linking of IgE on mast cells is a well-recognized trigger for AR. It has reported that nasal exposure of endotoxin-containing allergens can induce an IgE-independent, yet T-cell and histamine-dependent, nasal hypersensitivity-like reaction in mice [30]. Thus in the OVA-induced AR mice, NLRP3 deficiency might reduce the local Th2 inflammation through nonIgE-mediated pathway, and this phenomenon is informative for IgE-independent AR cases. Author contributions Z.X.Y., C.Q.L., T.Y.W., Q.Y.Z., M.X.Z., Y.C., H.P., Z.H.J., Y.D., and J.C.L. helped in collection and/or assembly of data; Z.X.Y., C.Q.L. T.Y.W. and Q.Y.Z. contributed to data analysis and manuscript writing; L.H.H. and L.J.C helped in design, data analysis, manuscript writing and final approval of the manuscript. Declaration of competing interest All authors declare no potential conflict of interest. Acknowledgements This work was supported by grants from the National Natural Science Foundation of China (81541038, 81670905, 81870702, 81770980), and the Shanghai Municipal Population and Family Planning Commission (201640182). We thank Prof. Du Bing for mice donation. References [1] A.N. Greiner, P.W. Hellings, G. Rotiroti, et al., Allergic rhinitis, Lancet 378 (2011) 2112e2122. [2] C. Bachert, E. Gevaert, Advances in rhinitis and rhinosinusitis in 2015, J. Allergy Clin. Immunol. 138 (2016) 1277e1283. [3] A.O. Eifan, S.R. Durham, Pathogenesis of rhinitis, Clin. Exp. Allergy 46 (2016) 1139e1151. [4] T. Iinuma, Y. Okamoto, Y. Morimoto, et al., Pathogenicity of memory Th2 cells is linked to stage of allergic rhinitis, Allergy 73 (2018) 479e489. [5] P.V. Tomazic, R. Birner-Gruenberger, A. Leitner, et al., Nasal mucus proteomic changes reflect altered immune responses and epithelial permeability in patients with allergic rhinitis, J. Allergy Clin. Immunol. 133 (2014) 741e750. [6] L.V. Blomster, J. Vukovic, D.A. Hendrickx, et al., CX3CR1 deficiency exacerbates neuronal loss and impairs early regenerative responses in the target-ablated olfactory epithelium, Mol. Cell. Neurosci. 48 (2011) 236e245. [7] M.R. de Zoete, N.W. Palm, S. Zhu, et al., Inflammasomes, Cold Spring Harb.
7
Perspect Biol. 6 (2014) a016287. [8] M. Lamkanfi, V.M. Dixit, Mechanisms and functions of inflammasomes, Cell 157 (2014) 1013e1022. [9] P. Broz, V.M. Dixit, Inflammasomes: mechanism of assembly, regulation and signaling, Nat. Rev. Immunol. 16 (2016) 407e420. [10] H. Guo, J.B. Callaway, J.P. Ting, Inflammasomes: mechanism of action, role in disease, and therapeutics, Nat. Med. 21 (2015) 677e687. [11] X. Dai, K. Sayama, M. Tohyama, et al., Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes, J. Allergy Clin. Immunol. 127 (2011) 806e814. [12] Y. Dombrowski, M. Peric, S. Koglin, et al., Honey bee (Apis mellifera) venom induces AIM2 inflammasome activation in human keratinocytes, Allergy 67 (2012) 1400e1407. [13] C. Liang, Z. Yang, Q. Zou, et al., Construction of an irreversible allergic rhinitisinduced olfactory loss mouse model, Biochem. Biophys. Res. Commun. 513 (2019) 635e641. [14] H.S. Kim, S. Won, E.K. Lee, et al., Effect of proparacaine in a mouse model of allergic rhinitis, Clin. Exp. Otorhinolaryngol. 10 (2017) 325e331. [15] J. Hou, Y. Zhou, Y. Zheng, et al., Hepatic RIG-I predicts survival and interferona therapeutic response in hepatocellular carcinoma, Cancer Cell 25 (2014) 49e63. [16] A. Baroja-Mazo, F. Martín-S anchez, A.I. Gomez, et al., The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response, Nat. Immunol. 15 (2014) 738e748. [17] B.S. Franklin, L. Bossaller, D. De Nardo, et al., The adaptor ASC has extracellular and ’prionoid’ activities that propagate inflammation, Nat. Immunol. 15 (2014) 727e737. [18] I.C. Allen, C.M. Jania, J.E. Wilson, et al., Analysis of NLRP3 in the development of allergic airway disease in mice, J. Immunol. 188 (2012) 2884e2893. [19] F. Madouri, N. Guillou, L. Fauconnier, et al., Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation, J. Mol. Cell Biol. 7 (2015) 351e365. [20] M. Ritter, K. Straubinger, S. Schmidt, et al., Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1b during acute allergic airway inflammation, Clin. Exp. Immunol. 178 (2014) 212e223. [21] K.N. Koch, M.L. Hartung, S. Urban, et al., Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma, J. Clin. Investig. 125 (2015) 3297e3302. [22] V. Hornung, A. Ablasser, M. Charrel-Dennis, et al., AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC, Nature 458 (2009) 514e518. [23] S.R. Kim, D.I. Kim, S.H. Kim, et al., NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation, Cell Death Dis. 5 (2014), e1498. [24] M. Platt, Pharmacotherapy for allergic rhinitis, Int Forum Allergy Rhinol 4 (2014) 35e40. [25] D.V. Wallace, M.S. Dykewicz, J. Oppenheimer, et al., Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters, Ann. Intern. Med. 167 (2017) 876e881. [26] T.H. Nguyen, T.B. Casale, Immune modulation for treatment of allergic disease, Immunol. Rev. 242 (2011) 258e271. [27] Y.L. Ye, Y.H. Chuang, B.L. Chiang, Strategies of mucosal immunotherapy for allergic diseases, Cell. Mol. Immunol. 8 (2011) 453e461. [28] F. Horak, VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis, Expert Opin. Investig. Drugs 20 (2011) 981e986. [29] P. Vashisht, T. Casale, Omalizumab for treatment of allergic rhinitis, Expert Opin. Biol. Ther. 13 (2013) 933e945. [30] N. Iwasaki, K. Matsushita, A. Fukuoka, et al., Allergen endotoxins induce Tcelledependent and noneIgE-mediated nasal hypersensitivity in mice, J. Allergy Clin. Immunol. 139 (2016) 258e268.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc
NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis Zixuan Yang 1, Caiquan Liang 1, Tianyu Wang 1, Qingyun Zou 1, Mengxia Zhou, Yin Cheng, Hu Peng, Zhenhua Ji, Yue Deng, Jianchun Liao**, Huanhai Liu* Department of Otolaryngology-Head and Neck Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China
a r t i c l e i n f o
a b s t r a c t
Article history: Received 17 October 2019 Accepted 5 November 2019 Available online xxx
Allergic rhinitis (AR) is a worldwide highly prevalent nasal inflammatory disease with elusive mechanisms about the regulation of innate immune response. The roles and mechanisms of NLRP3, a typical inflammasome, in AR development remain unclear. Here we investigate the roles of NLRP3 inflammasome activation in the development and progression of AR and try to uncover its potential mechanisms underlying. Wildtype and NLRP3 knockout mice were applied to construct the ovalbumin (OVA)-induced AR model. Caspase-1 specific inhibitor Belnacasan and inflammasome activator ATP were used for adjuvant stimulation of AR-model mice respectively. We found that the production of IL-1b and the activation of inflammasome were increased in both patients and mice with AR. NLRP3 deficiency markedly suppressed AR progression with reduced inflammatory response and epithelium pyroptosis in mice with AR. Furthermore, Caspase-1 inhibitor treatment in vivo ameliorated the development and progression of AR with favorable outcomes. Mechanistically, inflammation augments and nasal mucosa injury during AR were partially due to ASC-specks accumulation and subsequent cell pyroptosis. Our study reveals the previously unknown roles of NLRP3 inflammasome in promoting the development and progression of AR via enhancing inflammatory response and epithelium pyroptosis and thus provides a potential clue for allergic disease interventions. © 2019 Elsevier Inc. All rights reserved.
Keywords: NLRP3 Inflammasome IL-1b Allergic rhinitis Pyroptosis
1. Introduction With astonishing increasing new cases every year, allergic rhinitis (AR) has been recognized as one of the major chronic inflammatory upper airway diseases around the world, affecting approximately 20%e30% of the population [1]. Although AR is not fatal and frequently ignored, the effective treatments to cure AR is still unknown. AR patients suffer plenty of both physical discomfort and psychological stress with poor life quality [2]. Currently, several mechanisms underlying the development and regulation of AR have been proposed, with an intense concentration on Th2 immune response and eosinophils infiltration, which shares high similarities with allergic asthma [3,4]. Subsequently, inflammatory microenvironment results in the injury and impaired regeneration of nasal
* Corresponding author. ** Corresponding author. E-mail addresses: [email protected] (J. Liao), [email protected] (H. Liu). 1 These authors contribute equally to this work.
epithelium, which further interrupts the function of olfactory region [5]. Except for eosinophils, innate immune response has been reported to play an important role on the survival and regeneration of olfactory neuroepithelium [6]. However, the molecular mechanism of innate immune molecules in the development and progression of AR has not been thoroughly studied. Recently, inflammasomes activation after infection or stressstimulation has attracted much attention, which was studied most prominently in macrophages and dendritic cells [7]. Nod-like receptors (NLRs) are first discovered sensor proteins to form inflammasome complex, which associate with apoptosisassociated speck-like protein containing a CARD (ASC) through an amino-terminal pyrin domain [8]. Pro-caspase-1 are recruited to the inflammasome and cleaved into active caspase-1 [8]. Active caspase-1 containing cysteine-dependent protease activity, could cleave pro-IL-1b and pro-IL-18 into active IL-1b and IL-18, and then simultaneously induces an inflammatory form of cell death called pyroptosis [9]. Inflammasome activation has been demonstrated to be involved in diverse infectious and nonmicrobial diseases, including pathogenic infections of intestine and lung, gout,
https://doi.org/10.1016/j.bbrc.2019.11.031 0006-291X/© 2019 Elsevier Inc. All rights reserved.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
2
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
autoimmune diseases, Alzheimer’s disease, Type 2 diabetes and so on [10]. As to the allergic response, several studies have shown that certain allergens can trigger inflammasome activation, like house dust mite (HDT) and honey bee venom, which activates inflammasome in keratinocytes and macrophages [11,12]. However, the roles and mechanisms of the inflammasome activation in AR development remain unclear. To figure out the potential correlation between inflammasomes and AR, we detected the production of IL-1b and IL-18 in nasal lavage fluid (NLF) and found it was increased in AR patients compared with that in controls, indicating that activation of inflammasome might play important roles in the development of AR. Moreover, NLR family pyrin domain containing 3 (NLRP3) is the first and most thoroughly studied NLR, which could be induced by Toll-like receptor agonists and TNF-a in macrophages. Thus, we brought in Nlrp3 knockout (Nlrp3/) mice and inflammasome inhibitors for further investigation of the roles of inflammasome activation in nasal epithelium, aiming to discovering new target for AR treatment. 2. Materials and methods 2.1. Clinical specimens 40 AR patients (22 male and 18 female patients; age range, 17e67 years) and 14 healthy subjects (7 male and 7 female subjects; age range, 23e68 years) involved in this study are from Changzheng Hospital (Shanghai, China), who underwent nasal irrigation. Inferior turbinate mucosal samples were collected during septoplasty from the AR patient (female; age, 36 years; with AR and nasal septal deviation) and control (female; age, 26 years; with nasal septal deviation alone). This study was approved by the Ethics Committee of Second Military Medical University (Shanghai, China). All subjects gave written informed consent in accordance with the Declaration of Helsinki. All patients with AR had typical symptoms of perennial nasal allergy and the dust mite skin spot tests were positive. In this study, subjects were excluded if they had received any oral steroid within 3 months before the surgery. Topical steroids and antihistamines were withheld for a minimum of 1 month before the study. None had received antileukotrienes or immunotherapy. 2.2. Animals Six-week-old male C57BL/6 mice were from Shanghai SuperB&K laboratory animal Corp.Ltd. Nlrp3/ mice on a C57BL/6 background with 7bp deficiency at the promoter region of Nlrp3 were donated by Prof. Du Bing from East China Normal University. Mice were maintained under specific-pathogen-free animal laboratory with standard temperature and light controlled animal facility. All animal experiments were undertaken in accordance to the Institutional Animal Care and Use Committee (IACUC) guidelines of Second Military Medical University (Shanghai, China). 2.3. Reagents Antibodies specific to ASC, IL-1b, b-actin, cleaved Gasdermin D and horseradish peroxidase-coupled secondary antibodies were from Cell Signaling Technology. Antibody specific to ASC was from Santa Cruz. Antibodies specific to Caspase-1 and NLRP3 were from Abcam. Imject™ Alum Adjuvant was from ThermoFisher Scientific. Belnacasan (VX-765) was from Selleck. OVA (O-1000-100) was from Biosearch Technologies. DMSO, Lipopolysaccharides from Escherichia coli O111:B4, ATP, Cytotoxicity Detection kit and PEG300 were from Sigma-Aldrich. RPMI-1640 Medium and Fetal Bovine Serum
(FBS) was from Gibco™. 2.4. OVA-induced AR mice model Two stages were included in constructing OVA-induced AR mice model [13,14]. Mice were intraperitoneal injected with 25 mg OVA with 50 ml Imject®Alum as adjuvant once a week for 3 weeks, and controls received the same dosage of saline. One week after the last sensitization, mice were intranasal challenged with 20 ml OVA (50 mg/ml in saline, OVA group) or saline only (saline group) once a day for 7 consecutive days. Belnacasan was dissolved in control (ddH2O with 2% DMSO and 30% PEG 300) at the concentration of 5 mg/mL. Mice were intraperitoneal challenged with control or 5 mg/kg Belnacasan solution each once a day for 7 consecutive days, 10 min before or after OVA challenging. Mice were intraperitoneal challenged with saline (20 mL) or ATP (5 mM in saline) before OVA challenging. In Fig. 3E, mice were intraperitoneal challenged with control or 5 mg/kg Belnacasan each once a day for a week after 7-day-OVA intranasal administration. 15 min after intranasal challenge, frequencies of sneeze and scratch were measured within 15 min, and the data were shown by the average number per minute. The sinonasal cavity structure was processed for histologic analysis, and sinonasal mucosal tissues were harvested for qRT-PCR and Western blot assay. Blood samples were collected from the sinus retro-orbital rout under general anesthesia. 2.5. Cell lines and cultivation Human cell line THP-1 and human nasal epithelial cell line RPMI2650 were purchased from Cell Bank of the Shanghai Academy of life sciences and cultured in the RPMI-1640 medium with 10% FBS at 37 C in a 5% CO2 incubator. 2.6. RNA isolation and qRT-PCR analysis Total RNA was extracted from mice nasal mucosa tissues using TRIzol reagent (Invitrogen) following the manufacturer’s instructions. Real-Time PCR (qRT-PCR) analysis was performed using LightCycler (Roche) and SYBR RT-PCR kit (Takara) as previous introduction [15]. The relative expression level of the individual genes was normalized to that of internal control b-actin by using 2DDCt cycle threshold method. 2.7. Tissue immunohistochemistry (IHC) Nasal mucosa tissues were fixed in 4% PFA and then embedded with paraffin. Dewaxed 3-mm thick sections were treated with 3% H2O2 and then blocked with 3% BSA. Primary antibody were incubated at 4 C overnight. The next day, sections were incubated with secondary antibody for 1 h and then immunostaining was performed using Peroxidase/Diaminobenzidine (DAB) Substrate Kit (Dako) following the standard protocol as we described previously [13]. Photos were taken with Olympus BX53 microscope. 2.8. Immunofluorescence (IF) analysis THP-1 cells slides were labeled with rabbit ASC specific antibody overnight, then labeled with Alexa Fluor 488 mouse anti-rabbit IgG for 1 h, finally coated with fluoroshield mounting medium containing DAPI (ab104139) following the standard protocol as we described previously [13]. Labeled cells slides were viewed with a Zeiss LSM 510 confocal laser microscope.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
3
3. Results
IL-1b and IL-18 in the NLF of AR patients and controls, which showed higher of AR patients than that of controls (Fig. 1A). And patients with mild persistent AR showed lower production of IL-1b than that in patients with moderate to severe persistent AR (Fig. 1A). Furthermore, the production of IL-1b and level of caspase1 were both increased in the inferior turbinate mucosal tissues of AR patients, which were determined by IHC analysis, indicating the crucial roles of inflammasome activation in AR development (Fig. 1B). Simultaneously, we constructed OVA-induced AR mice model, and the behavioral measures of AR indicated that this model had successfully mimicked AR development (Fig. 1C). Whereafter, the production of IL-1b in NLF of mice were detected by ELISA, which also determined increased production of IL-1b during AR development (Fig. 1D). Moreover, IHC analysis showed that AR mice exhibited advanced injury of nasal epithelium tissues, and enhanced expression of ASC, caspase-1 and IL-1b than those of controls (Fig. 1E and F). These data suggest that inflammasome activation might play important roles in the development of AR.
3.1. The production of IL-1b and the activation of inflammasome are increased in both patients and mice with AR
3.2. NLRP3 deficiency inhibits AR progression through alleviating inflammation response in vivo
In order to demonstrate the roles of the inflammasome involving in AR development, we first compared the production of
Currently, the potential function of inflammasome in the AR development is still unconcerned especially lacking in vivo
2.9. ASC-speck isolation and purification ASC-specks were purified from LPS-primed cells activated with ATP, and then passed through a “cushion” of 50% Percoll in CHAPS buffer (20 mM HEPES-KOH, pH 7.5, 5 mM MgCl2, 0.5 mM EGTA, 0.1 mM PMSF and 0.1% CHAPS) for purification. After that, ASCspecks had been washed with 0.5 ml CHAPS buffer and dissolved in PBS. The method of purification is verified as previously described [16,17]. 2.10. Statistics Data are presented as mean ± SD. Statistical comparisons between experimental groups were analyzed by unpaired Student’s ttest in SPSS 17.0 (Chicago, IL), and a two-tailed p < 0.05 was taken to indicate statistical significance. The p values and hazard ratios were shown as indicated. (*, p < 0.05, **, p < 0.01, ***, p < 0.001).
Fig. 1. The production of IL-1b and the activation of inflammasome are increased in both patients and mice with AR. (A) The production of IL-1b and IL-18 in the NLF of AR patients (n ¼ 40) and healthy controls (n ¼ 14) were examined by ELISA analysis. Data are shown as mean ± SD. (B) Representative IHC images show the production of IL-1b and Caspase-1 in the inferior turbinate mucosal tissues. (C) Frequency of scratching and sneezing were examined Caspase in the OVA-induced AR model and control mice. (D) The production of IL-1b in the NLF of mice was examined by ELISA analysis. (E) Representative IHC images show the expression of ASC, IL-1b, and Caspase-1 in the nasal mucosa tissues of mice. (F) Levels of ASC, IL-1b, cleaved Caspase-1 and GSDMD-N was measured by Western blot. The two blots are from two representative of the five mice per group. For CeF, data are shown as mean ± SD (n ¼ 5) or photographs from one representative experiment of three independent experiments. **, p < 0.01, ***p < 0.001.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
4
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
evidence. To further explore this issue, we brought in NLRP3 deficient mice (Nlrp3/), the most studied inflammasome, which showed no abnormality in nasal symptoms of sneezing and scratch (Fig. 2A). Applied with OVA-induced AR model, Nlrp3/ mice exhibited decreased AR symptoms of sneezing and scratch than those of wild-type (WT) mice (Fig. 2A). IHC and Western blot analysis of nasal mucosa confirmed that NLRP3 deficiency effectively inhibited the inflammasome activation in AR mice (Fig. 2B and C). Moreover, the production of IL-1b in NLF of Nlrp3/ mice increased than that of controls (Fig. 2D). Since AR is a typical IgEmediated type I allergic reaction, we compared the content of IgE in the serum between Nlrp3/ and WT mice and found no significant differences (Fig. 2E). Next, we examined the production of
some proinflammatory cytokine and chemokine, and found the production of IL-6, CXCL9 and CXCL10 was decreased in the nasal mucosa tissues of Nlrp3/ mice (Fig. 2F). Furthermore, eosinophils have been considered to play important roles in AR development, thus we detected the cytokines and protein associated with eosinophils activation. And the results showed that NLRP3 deficiency markedly inhibited the production of IL-4, IL-5, IL-13 and the expression of EAR1 in the OVA-induced AR model (Fig. 2F and G). Gasdermin D-N terminal (GSDMD-N), the marker of cell pyroptosis, was reduced in the nasal mucosa tissues of Nlrp3/ mice (Fig. 2H). These data further demonstrate that NLRP3 inflammasome activation contributes to the AR development independent on IgE production.
Fig. 2. NLRP3 deficiency alleviates the AR symptom of mice. Nlrp3/ and WT mice (n ¼ 5) were applied with OVA-induced AR model and nasal mucosa tissues were extracted for examination. (A) Frequency of scratching and sneezing of mice were measured. (B) Representative IHC images show the expression of NLRP3, IL-1b, and Caspase-1 in the nasal mucosa tissues of mice. (C) Levels of NLRP3, IL-1b, and cleaved Caspase-1 were measured by Western blot. (D) The production of IL-1b in the NLF of mice was examined by ELISA analysis. (E) The concentration of IgE in serum of mice was measured by ELISA analysis. (F) Productions of Il-6, Cxcl9, Cxcl10, Il-4, Il-5, and Il-13 were measure by qRT-PCR analysis. (G) The expression of Ear1 was measure by qRT-PCR analysis. (H) Levels of GSDMD-N were measured by Western blot. Data are shown as mean ± SD (n ¼ 5) or photographs from one representative experiment of three independent experiments. *, p < 0.05, **, p < 0.01, ***, p < 0.001.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
5
Fig. 3. Caspase-1 inhibitor ameliorates the AR development. Mice after sensitization were adjuvant challenged with saline or Belnacasan once a day 10 min before OVA challenging (Belnacasan before OVA group) or 10 min after OVA challenging (Belnacasan after OVA group). Mice after sensitization were adjuvant challenged with saline or ATP before OVA challenging (ATP þ OVA group). Mice after 7-day-OVA intranasal administration were challenged with saline or Belnacasan once a day (Belnacasan group). Nasal mucosa tissues were extracted for examination. (n ¼ 5) (A) Representative IHC images show the expression Caspase-1 and IL-1b in the nasal mucosa tissues from OVA-induced AR mice with or without Caspase-1 inhibitor treatment. (B) Levels of IL-1b, and cleaved Caspase-1 were measured by Western blot. (CeE) Frequency of scratching and sneezing of mice were measured in OVA-induced AR mice with Caspase-1 inhibitor or inflammasome activator treatment. (F) The concentration of IgE in serum of mice was measured by ELISA analysis. (G) Productions of Il-6, Cxcl9, Il-4, and expression of Ear1 were measure by qRT-PCR analysis. Data are shown as mean ± SD or photographs from one representative experiment of three independent experiments. *, p < 0.05, **, p < 0.01.
3.3. Caspase-1 inhibitor effectively ameliorates the development of AR As inflammasome activation promotes the development of AR, we consider its possibility to be a potential treatment target with further investigation. Therefore, we applied caspase-1 specific inhibitor (Belnacasan) and inflammasome activator (ATP) adjuvant with OVA through intranasal administration to induce AR respectively. IHC and Western blot analysis of nasal mucosa tissues verified the efficiency of Belnacasan and ATP in inflammasome activation (Fig. 3A and B). The results of AR behavioral symptoms indicated that the inflammasome inhibition dramatically alleviated the development of AR, and conversely inflammasome overactivation aggravated AR development (Fig. 3C and D). We further wondered the function of this inhibitor treatment in the later phase of AR. After OVA intranasal administration for 7 days to successfully establish AR model, mice were treated with Belnacasan for another week. To be excited, we found that the mice exhibited improved AR symptoms (Fig. 3E). Likewise the phenomenon in Nlrp3/ mice, the content of IgE in the serum had no significant change after Belnacasan administration (Fig. 3F). Next, we investigated the production of
proinflammatory cytokines, chemokines, and eosinophilassociated proteins in the nasal mucosa during AR development. The results showed that the production of IL-6, CXCL9, IL-4 and the expression of EAR1 decreased after Belnacasan treatment at mRNA levels (Fig. 3G). Taken together, these proofs further demonstrate that inflammasome inhibition could relieve AR symptoms by inhibiting the inflammatory responses. 3.4. Nasal mucosa injury during AR results from ASC-specks accumulation and subsequent cell pyroptosis Inflammasome activation triggers a form of cell death, called pyroptosis, to protect against infectious agents and cause tissue injury [10], and ASC-specks could be released into extracellular space and uptake by vicinal cells, which retain their ability to mature IL-1b and facilitate cell pyroptosis [16,17]. Since we observed damaged epithelium region with high-expressed IL-1b and Caspase-1 in AR nasal mucosa tissues (Fig. 1B and E), we wondered if ASC-speck accumulation and associated nasal epithelium pyroptosis contributed to the inflammation augments during AR development. To validate this assumption, we applied LPS and ATP stimulus on THP-1 cells respectively, isolated ASC-specks, and
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
6
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
Fig. 4. ASC-specks accumulation and subsequent cell pyroptosis result in epithelial injury. (A) IF staining of ASC was shown of LPS-primed THP-1 cells which then activated with ATP. (BeF) RPMI2650 cells were primed with LPS (1ug/ml) for 6 h and then stimulated with ASC-speck (100ug/ml) for 1 h. IF staining of ASC was shown (B). Production of IL-1b was measured in supernatants by ELISA analysis (C). Levels of IL-1b and cleaved Caspase-1 were detected by Western blot (D). Levels of GSDMD-N were detected by Western blot (E). Quantification of LDH was measured in supernatants (F). Data are shown as mean ± SD (n ¼ 3) or photographs from one experiment of three independent experiments. *, p < 0.05, **, p < 0.01.
stimulated RPMI2650 epithelial cells by LPS and ASC-specks in turn. IF staining showed that ASC-specks formed around the cell membrane in THP-1 cells after inflammasome activation (Fig. 4A), and epithelium could uptake ASC-specks from the supernatant (Fig. 4B). Moreover, the production of IL-1b, cleavage of caspase-1 and GSDMD-N, and the release of LDH were all increased, which indicated that ASC-specks accumulation promoted the nasal epithelium pyroptosis and amplified inflammation (Fig. 4CeF). These results demonstrate that nasal epithelium pyroptosis could be induced by ASC-specks accumulation and augmented inflammation. 4. Discussion The roles of NLRP3 inflammasome and caspase-1 activation in the allergic diseases have attracted much attention recent years, which remains controversial with different allergens like OVA or HDT [18e20]. In our experiments, NLRP3 deficiency alleviates AR progression in the OVA-induced AR mice. Currently, there’s no agreement with a universal mechanism for the NLRP3 inflammasome activation, which occupies multiple effects on cell physiology through IL-1b and IL-18 signaling pathway. It is reported that Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma owing to the function of IL-18 in Treg differentiation [21]. These converse effects of NLRP3 inflammasome in allergic diseases might due to different allergens, tissue microenvironments and downstream activation signaling of NLRP3 inflammasome. Thus, the roles of NLRP3 inflammasome in other allergens-induced allergic airway diseases need to be further studied. In this research, we demonstrated that NLRP3 deficiency or caspase-1 inhibition could relieve AR progression, refrain inflammation response and protect nasal mucosa in vivo. However, caspase-1 and IL-1b cleavage could be activated by multiple inflammasome members, for instance other NLRs and absent in
melanoma 2 (AIM2)-like family members [22]. Thus, we couldn’t rule out the roles of other inflammasomes in the development of AR currently. Moreover, it is reported that AIM2 inflammasome could promote Th2 allergic responses through IL-1b and IL-18 production [12] and intracellular DNA is a classical activator of AIM2 inflammasome [22]. Hence, we couldn’t exclude the possibility that AIM2 inflammasome might be activated by intracellular DNA released during nasal mucosa injury to facilitate AR progression. Thus, whether NLRP3 inflammasome activation promotes AR progression alone or cooperates with other inflammasome members is a critical problem and warrants further investigation. Previous report demonstrated that in the airway epithelial cells, as important immune responders, mitochondrial ROS modulated the allergic airway inflammation through the regulation of NLRP3 inflammasome activation [23]. Here, we confirmed that pyroptosis of epithelium induced by NLRP3 inflammasome activation in nasal mucosa partially contributed to the AR development in vivo and in vitro. However, except for olfactory mucosa epithelium, whether there exists pyroptosis of olfactory neuron or other cells in the nasal microenvironment need to be further figured out more precisely using NLRP3 conditional knockout mice. At present, pharmacotherapies for AR are the mainly treatments to target specific symptoms [24,25], however the current AR treatments cannot achieve the purpose of radical cure. Nowadays, immune modulator therapies provide new approaches for AR treatment and acquire some achievements while still exist some problems [26,27]. For instance, a new TLR8 agonist provides nearterm symptom relief for AR treatment with unclear immunologic mechanisms and uncertain long-term immunomodulatory benefits [28]. Besides, anti-IgE antibodies also exhibit efficacy in AR clinical trials with some limitations of high costs and intravenous therapy [29]. Thus developing more effective treatment schedules of AR is urgently needed, our findings demonstrated that caspase-1 inhibition could effectively relieve symptom of mice both during and after OVA induction, providing a new option for allergy subjects
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031
Z. Yang et al. / Biochemical and Biophysical Research Communications xxx (xxxx) xxx
with rapid onset of symptom control and longer-term immunomodulation. Here, we demonstrated NLRP3 deficiency or caspase-1 inhibition suppressed AR progression without serum IgE alteration. Although allergen-mediated cross-linking of IgE on mast cells is a well-recognized trigger for AR. It has reported that nasal exposure of endotoxin-containing allergens can induce an IgE-independent, yet T-cell and histamine-dependent, nasal hypersensitivity-like reaction in mice [30]. Thus in the OVA-induced AR mice, NLRP3 deficiency might reduce the local Th2 inflammation through nonIgE-mediated pathway, and this phenomenon is informative for IgE-independent AR cases. Author contributions Z.X.Y., C.Q.L., T.Y.W., Q.Y.Z., M.X.Z., Y.C., H.P., Z.H.J., Y.D., and J.C.L. helped in collection and/or assembly of data; Z.X.Y., C.Q.L. T.Y.W. and Q.Y.Z. contributed to data analysis and manuscript writing; L.H.H. and L.J.C helped in design, data analysis, manuscript writing and final approval of the manuscript. Declaration of competing interest All authors declare no potential conflict of interest. Acknowledgements This work was supported by grants from the National Natural Science Foundation of China (81541038, 81670905, 81870702, 81770980), and the Shanghai Municipal Population and Family Planning Commission (201640182). We thank Prof. Du Bing for mice donation. References [1] A.N. Greiner, P.W. Hellings, G. Rotiroti, et al., Allergic rhinitis, Lancet 378 (2011) 2112e2122. [2] C. Bachert, E. Gevaert, Advances in rhinitis and rhinosinusitis in 2015, J. Allergy Clin. Immunol. 138 (2016) 1277e1283. [3] A.O. Eifan, S.R. Durham, Pathogenesis of rhinitis, Clin. Exp. Allergy 46 (2016) 1139e1151. [4] T. Iinuma, Y. Okamoto, Y. Morimoto, et al., Pathogenicity of memory Th2 cells is linked to stage of allergic rhinitis, Allergy 73 (2018) 479e489. [5] P.V. Tomazic, R. Birner-Gruenberger, A. Leitner, et al., Nasal mucus proteomic changes reflect altered immune responses and epithelial permeability in patients with allergic rhinitis, J. Allergy Clin. Immunol. 133 (2014) 741e750. [6] L.V. Blomster, J. Vukovic, D.A. Hendrickx, et al., CX3CR1 deficiency exacerbates neuronal loss and impairs early regenerative responses in the target-ablated olfactory epithelium, Mol. Cell. Neurosci. 48 (2011) 236e245. [7] M.R. de Zoete, N.W. Palm, S. Zhu, et al., Inflammasomes, Cold Spring Harb.
7
Perspect Biol. 6 (2014) a016287. [8] M. Lamkanfi, V.M. Dixit, Mechanisms and functions of inflammasomes, Cell 157 (2014) 1013e1022. [9] P. Broz, V.M. Dixit, Inflammasomes: mechanism of assembly, regulation and signaling, Nat. Rev. Immunol. 16 (2016) 407e420. [10] H. Guo, J.B. Callaway, J.P. Ting, Inflammasomes: mechanism of action, role in disease, and therapeutics, Nat. Med. 21 (2015) 677e687. [11] X. Dai, K. Sayama, M. Tohyama, et al., Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes, J. Allergy Clin. Immunol. 127 (2011) 806e814. [12] Y. Dombrowski, M. Peric, S. Koglin, et al., Honey bee (Apis mellifera) venom induces AIM2 inflammasome activation in human keratinocytes, Allergy 67 (2012) 1400e1407. [13] C. Liang, Z. Yang, Q. Zou, et al., Construction of an irreversible allergic rhinitisinduced olfactory loss mouse model, Biochem. Biophys. Res. Commun. 513 (2019) 635e641. [14] H.S. Kim, S. Won, E.K. Lee, et al., Effect of proparacaine in a mouse model of allergic rhinitis, Clin. Exp. Otorhinolaryngol. 10 (2017) 325e331. [15] J. Hou, Y. Zhou, Y. Zheng, et al., Hepatic RIG-I predicts survival and interferona therapeutic response in hepatocellular carcinoma, Cancer Cell 25 (2014) 49e63. [16] A. Baroja-Mazo, F. Martín-S anchez, A.I. Gomez, et al., The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response, Nat. Immunol. 15 (2014) 738e748. [17] B.S. Franklin, L. Bossaller, D. De Nardo, et al., The adaptor ASC has extracellular and ’prionoid’ activities that propagate inflammation, Nat. Immunol. 15 (2014) 727e737. [18] I.C. Allen, C.M. Jania, J.E. Wilson, et al., Analysis of NLRP3 in the development of allergic airway disease in mice, J. Immunol. 188 (2012) 2884e2893. [19] F. Madouri, N. Guillou, L. Fauconnier, et al., Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation, J. Mol. Cell Biol. 7 (2015) 351e365. [20] M. Ritter, K. Straubinger, S. Schmidt, et al., Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1b during acute allergic airway inflammation, Clin. Exp. Immunol. 178 (2014) 212e223. [21] K.N. Koch, M.L. Hartung, S. Urban, et al., Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma, J. Clin. Investig. 125 (2015) 3297e3302. [22] V. Hornung, A. Ablasser, M. Charrel-Dennis, et al., AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC, Nature 458 (2009) 514e518. [23] S.R. Kim, D.I. Kim, S.H. Kim, et al., NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation, Cell Death Dis. 5 (2014), e1498. [24] M. Platt, Pharmacotherapy for allergic rhinitis, Int Forum Allergy Rhinol 4 (2014) 35e40. [25] D.V. Wallace, M.S. Dykewicz, J. Oppenheimer, et al., Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters, Ann. Intern. Med. 167 (2017) 876e881. [26] T.H. Nguyen, T.B. Casale, Immune modulation for treatment of allergic disease, Immunol. Rev. 242 (2011) 258e271. [27] Y.L. Ye, Y.H. Chuang, B.L. Chiang, Strategies of mucosal immunotherapy for allergic diseases, Cell. Mol. Immunol. 8 (2011) 453e461. [28] F. Horak, VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis, Expert Opin. Investig. Drugs 20 (2011) 981e986. [29] P. Vashisht, T. Casale, Omalizumab for treatment of allergic rhinitis, Expert Opin. Biol. Ther. 13 (2013) 933e945. [30] N. Iwasaki, K. Matsushita, A. Fukuoka, et al., Allergen endotoxins induce Tcelledependent and noneIgE-mediated nasal hypersensitivity in mice, J. Allergy Clin. Immunol. 139 (2016) 258e268.
Please cite this article as: Z. Yang et al., NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis, Biochemical and Biophysical Research Communications, https://doi.org/10.1016/j.bbrc.2019.11.031